Limited FDA Approval Off-Label Use Risks
FDA · TGA · WADA · peer-reviewed literature Updated May 2026 Reviewed by Allmeds AI Pharmacist

Sermorelin Benefits: Approved Use Cases vs Off-Label Marketing

Sermorelin is a GHRH analogue with a narrow FDA-approved history (paediatric GH-deficiency under specialist supervision; GH-axis diagnostic testing). It is widely marketed off-label for anti-aging, sleep, body composition, and longevity. The off-label benefit claims are not supported by FDA-approved indications. This page distinguishes the approved use from the marketed claims.

Sermorelin has limited FDA-approved indications, primarily paediatric GH-deficiency under specialist supervision and as a diagnostic agent for GH-axis testing. Marketed benefits for anti-aging, sleep, and body composition in healthy adults are off-label and not regulator-supported. The published evidence for those uses is limited.

Key Takeaways

  • Sermorelin is a GHRH analogue that stimulates pulsatile GH release from the pituitary.
  • FDA-approved historical use is narrow: paediatric GH-deficiency under specialist supervision and as a GH-axis diagnostic.
  • Marketed off-label benefits for anti-aging, sleep, and body composition are not regulator-supported.
  • Compounded sermorelin sold for anti-aging is not pharmaceutical-grade for that use.
  • Stimulating the GH/IGF-1 axis carries labelled risks (fluid retention, glucose intolerance, joint pain) per the FDA label for tesamorelin and other GH-axis products.

What sermorelin is approved for

Sermorelin (Geref) had FDA-approved use historically in two contexts: as a GH-axis diagnostic agent for stimulation testing in suspected GH deficiency, and as a treatment for paediatric GH-deficiency under specialist supervision. The Geref brand was withdrawn in 2008 for commercial reasons unrelated to safety, leaving sermorelin available through compounding pharmacies for prescribed uses.

What sermorelin is marketed for off-label

Online and clinic marketing describes sermorelin for anti-aging, improved sleep quality, body composition, recovery, and longevity in healthy adults. These uses are off-label. They are not supported by FDA-approved indications, and the published evidence specifically supporting them is limited.

What the published evidence shows for off-label use

Sermorelin stimulates pulsatile GH release in a pattern more physiological than recombinant human growth hormone (rhGH). Mechanistic plausibility for some claimed benefits exists. The published clinical evidence for off-label anti-aging, sleep, and body-composition uses is limited and does not meet the regulator threshold for label expansion. Stimulating the GH/IGF-1 axis carries labelled risks (fluid retention, glucose intolerance, joint pain) described in the FDA label for the related drug tesamorelin (Egrifta).

Check your medications before any change

Allmeds scans interactions across your full list. Free for individuals; team plans available.

Try it free → Talk to Sales

Common Questions

Is sermorelin FDA approved for anti-aging?

No. Sermorelin's FDA-approved historical use is narrow (paediatric GH-deficiency, GH-axis diagnostic testing). Anti-aging is not an approved indication.

Does sermorelin work for anti-aging?

The published clinical evidence specifically supporting anti-aging benefit claims is limited and does not meet regulator standards for an FDA label expansion. Patients should discuss any planned use with a clinician.

Is sermorelin safer than recombinant human growth hormone?

Sermorelin produces pulsatile GH release that is closer to natural physiology than the steady supraphysiological GH levels seen with rhGH. Whether this translates to a meaningfully different safety profile in off-label populations is not characterised by regulator-supported trials.

Can I get sermorelin through a compounding pharmacy?

Compounded sermorelin is available through some pharmacies under prescription. Compounded products are not pharmaceutical-grade in the same sense as approved manufactured products. Discuss with your prescribing clinician.

References

  1. Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. Source.
  2. U.S. Food & Drug Administration. Egrifta (tesamorelin) prescribing information. Source.
  3. U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Source.
  4. Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). Source.
Not medical advice. This page summarises regulator statements and peer-reviewed literature for general information. It is not a substitute for professional medical advice. Speak to your doctor or pharmacist before starting, stopping, or changing any medicine.